GRPR and neoplasm: Given that this enzyme is overexpressed in tumour cells by the lysosomes, the premature release of the toxin in the bloodstream should be prevented, whereas it should occur in the cancerous cells, after the receptor-mediated endocytosis, triggered by the binding between targeting peptide and GRP-R.